S100A12 ELISA

pS100A12 ELISAbr /
img alt=For Research Use Only src=http://www.alpco.com/img/ruo.gif align=absMiddle / For Research Use Only/p
div class=prod_head_infohr /
/div
div class=prod_spec_box
div class=prod_specbFormat:/b/div
div class=prod_spec_infoELISA / EIA/div
/div
div class=prod_spec_box
div class=prod_specSample Type:/div
div class=prod_spec_infostool/div
/div
div class=prod_spec_box
div class=prod_specbSample Size:/b/div
div class=prod_spec_info100 mg/div
/div
div class=prod_spec_box
div class=prod_specbSize:/b/div
div class=prod_spec_info96 wells/div
/div
div class=prod_spec_box
div class=prod_specbRange:/b/div
div class=prod_spec_info0.22 - 6.0 ng/ml/div
/div
div class=prod_spec_box
div class=prod_specbSensitivity:/b/div
div class=prod_spec_info0.016 ng/ml/div
/div
div class=prod_spec_box
div class=prod_specbIncubation Time:/b/div
div class=prod_spec_info2 hour(s)/div
div class=prod_spec_info
pbSummary:/b/p
Fecal S100A12 is a novel non-invasive marker which allows the distinction between IBD and Irritable Bowel Syndrome (IBS) as well as viral infections with high sensitivity and specificity. The calcium binding protein is expressed in the cytosol of granulocytes and released into the inflammatory tissue. The protein interacts with the RAGE-receptor on endothelial cells, mononuclear phagocytes and lymphocytes and triggers pro-inflammatory processes. br /
br /
IBD Patients, suffering from Crohnlsquo;s disease or ulcerative colitis exhibit significantly elevated S100A12 levels compared to healthy individuals or patients with IBS. (Foell et al. 2008; Sidler et al. 2008; Kaiser et al. 2007; de Jong et al. 2006).
pnbsp;/p
/div
/div
pnbsp;/p